TrkB-expressing paraventricular hypothalamic neurons suppress appetite through multiple neurocircuits

Juan Ji An¹, Clint E. Kinney¹, Guey-Ying Liao¹, Eric J. Kremer², and Baoji Xu¹*

¹Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL 33458, USA
²Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France

*Correspondence:
Dr. Baoji Xu, Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL 33458, USA; Phone: 561-228-2340; Fax: 561-228-2341; Email: bxu@scripps.edu
ABSTRACT

The TrkB receptor is critical for the control of energy balance, as mutations in its gene (NTRK2) lead to hyperphagia and severe obesity in humans and mice. The main neural substrate mediating the appetite-suppressing activity of TrkB, however, remains unknown. Here, we demonstrate that selective Ntrk2 deletion within the paraventricular hypothalamus (PVH) leads to severe hyperphagic obesity. Furthermore, chemogenetic activation or inhibition of TrkB-expressing PVH (PVH\textsuperscript{TrkB}) neurons suppresses or increases food intake, respectively. PVH\textsuperscript{TrkB} neurons project to multiple brain regions, including the ventromedial hypothalamus (VMH) and the lateral parabrachial nucleus (LPBN). We found that PVH\textsuperscript{TrkB} neurons projecting to LPBN are distinct from those projecting to VMH, yet Ntrk2 deletion in PVH neurons projecting to either VMH or LPBN results in hyperphagia and obesity. Therefore, TrkB signaling is a key regulator of a previously uncharacterized and heterogenous neuronal population within the PVH that impinges upon multiple circuits to govern appetite.

INTRODUCTION

The regulation of food intake is essential for survival in all organisms, and its dysregulation not only affects survival but also causes health problems such as obesity. Several ligand-receptor pairs play a crucial role in the central regulation of energy balance. They include leptin and the leptin receptor, alpha-melanocyte-stimulating hormone (\(\alpha\)MSH) and the melanocortin-4 receptor (MC4R), and brain-derived neurotrophic factor (BDNF) and the TrkB receptor. Defects in any of these three ligand-receptor pairs lead to severe obesity in humans\textsuperscript{1-5} and mice\textsuperscript{6-11}. Furthermore, several common single nucleotide polymorphisms in the MC4R and BDNF genes have been found to be associated with increased body mass index in large-scale genome-wide association studies\textsuperscript{12-15}. Remarkable progress has been made in elucidation of neural circuits that mediate the effects of leptin and \(\alpha\)MSH on energy balance\textsuperscript{16}. By comparison, much less is known about
the neural substrate through which the BDNF-TrkB pathway regulates appetite and energy expenditure.

BDNF is well known for its role in neuronal development and synaptic function\textsuperscript{17-19}. It signals through the binding of two distinct classes of receptor proteins: the tropomyosin receptor kinase B (TrkB) and the p75 neurotrophin receptor (p75\textsuperscript{NTR}). Mutations in the \textit{NTRK2} gene, which codes for TrkB, lead to severe obesity in mice and humans\textsuperscript{4,11}. Conversely, no obesity phenotype has been observed in mice lacking the p75\textsuperscript{NTR} receptor\textsuperscript{20}. In fact, mice lacking the p75\textsuperscript{NTR} receptor are protected from obesity induced by high-fat diet and remain lean due to increased energy expenditure\textsuperscript{21}. Therefore, BDNF should signal through TrkB to regulate energy balance. The paraventricular hypothalamus (PVH) and the ventromedial hypothalamus (VMH) have been identified as two important brain areas that express BDNF to suppress food intake and promote energy expenditure\textsuperscript{22-24}. However, it remains unclear in which population of hypothalamic neurons TrkB is required for the control of energy balance and how these TrkB-expressing neurons regulate food intake and/or energy expenditure. Our recent work found that \textit{Ntrk2} deletion in the dorsomedial hypothalamus (DMH) led to modest hyperphagia and obesity\textsuperscript{26}, but to a much lesser extent in comparison with \textit{Ntrk2} hypomorphic mice in which \textit{Ntrk2} expression is reduced to a quarter of the normal amount throughout the body\textsuperscript{11}, indicating that the main neural substrate underlying the action of TrkB signaling on energy balance remains to be identified.

Here we report that TrkB-expressing PVH (PVH\textsuperscript{TrkB}) neurons are distinct from neurons that express BDNF, MC4R, or prodynorphin (PDYN) in the PVH, the three subtypes of neurons that are known to suppress appetite\textsuperscript{22,27,28}. We found that chemogenetic inhibition of PVH\textsuperscript{TrkB} neurons greatly increased food intake, whereas chemogenetic activation of these neurons drastically reduced food intake. Furthermore, we found that deletion of the \textit{Ntrk2} gene in the PVH led to severe hyperphagic obesity. We then designed a projection-specific gene deletion approach and used this approach to reveal that PVH\textsuperscript{TrkB} neurons project to the VMH and the lateral parabrachial nucleus (LPBN) to suppress food intake. These studies not only identify the main neural substrate
by which TrkB signaling regulates energy balance, but also implicates the PVH → VMH neurocircuit in the control of appetite.

RESULTS

Many TrkB neurons in the PVH are distinct from previously defined ones

The PVH is a heterogeneous brain structure with many different cell types. At least 10 types of PVH neurons can be molecularly defined by the expression of BDNF, corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), MC4R, oxytocin, prodynorphin (PDYN), somatostatin, tyrosine hydroxylase, thyrotropin-releasing hormone (TRH), and vasopressin. We previously found that approximately 5% PVH-TrkB neurons expressed BDNF. We sought to determine whether PVH-TrkB neurons belong to other defined neuronal populations.

TrkB antibodies do not mark cell bodies well in brain sections, because TrkB is distributed to the membrane of both cell bodies and processes. We employed the Ntrk2CreER/+ mouse strain, in which the Cre-ERT2 sequence is inserted into the Ntrk2 locus immediately after the first coding ATG, for colocalization studies. We crossed Ntrk2CreER/+ mice to Rosa26Ai9/+ mice to generate Ntrk2CreER/+;Rosa26Ai9/+ mice, in which TrkB-expressing cells express tdTomato after tamoxifen treatment. Since the kinase-lacking truncated TrkB is expressed in astrocytes, tdTomato should also label astrocytes. We detected many tdTomato-labelled TrkB cells in the PVH (Fig. 1a), which are either neurons that are positive for the neuronal marker NeuN (Supplementary Fig. 1a) or astrocytes that are positive for glial fibrillary acidic protein (Supplementary Fig. 1b). We noticed that there was a high colocalization between TrkB and oxytocin in the PVH (18% TrkB neurons express oxytocin and 51% oxytocin neurons express TrkB; Fig. 1b). In addition, a small number of PVH-TrkB neurons express TRH (2% TrkB neurons express TRH and 12% TRH neurons express TrkB; Fig. 1c), PDYN (6% TrkB neurons express PDYN and 17% PDYN neurons express TrkB; Fig. 1d), somatostatin (2% TrkB neurons express somatostatin and 16% somatostatin neurons
express TrkB; Supplementary Fig. 1c) and GHRH (5% TrkB neurons express GHRH and 30% GHRH neurons express TrkB; Supplementary Fig. 1d). Note that higher percentages of PVH^TrkB neurons are positive for these markers in the shown images (Fig. 1 and Supplementary Fig. 1), because the images were taken from the area where these markers are expressed. Very few PVH^TrkB neurons express CRH (Fig. 1e), tyrosine hydroxylase (Supplementary Fig. 1e), or vasopressin (Supplementary Fig. 1f). We also examined colocalization of TrkB with MC4R in the PVH using the BAC Mc4r-EGFP mouse strain. We only detected low colocalization of TrkB with MC4R in the PVH of tamoxifen-treated Ntrk2^CreER^{2+/+};Rosa26^Alb/++;Mc4r-EGFP mice (3% TrkB neurons express MC4R and 10% MC4R neurons express TrkB; Fig. 1f). These results indicate that the majority of PVH^TrkB neurons are distinct from previously defined neuronal populations.

**Deletion of the Ntrk2 gene with Sim1-Cre leads to obesity**

We previously reported that Ntrk2 deletion in several hypothalamic areas using the Rgs9-Cre led to obesity; however, the obesity phenotype was not as severe as what we observed in Ntrk2 hypomorphic mice that express TrkB at ~25% of the normal amount throughout the body. Given that Rgs9-Cre only deletes Ntrk2 in a small number of PVH neurons and that stereotaxic injection of recombinant BDNF into the PVH reduces food intake and increases energy expenditure, this observation raises the possibility that TrkB expressed in the PVH (PVH TrkB hereafter) plays an important role in the control of energy balance. We tested this possibility by deleting Ntrk2 in the PVH.

We tested whether Sim1-Cre is suitable for abolishment of Ntrk2 gene expression in the PVH by crossing Sim1-Cre mice to Ntrk2^{2BZ/+} mice to generate Sim1-Cre;Ntrk2^{2BZ/+} mice, in which β-galactosidase is expressed in otherwise TrkB-expressing neurons once the floxed Ntrk2^{2BZ} allele is deleted by Cre recombinase as shown in our previous studies. We detected many cells expressing β-galactosidase in the PVH (Fig. 2a), suggesting that Sim1-Cre is effective in abolishing TrkB expression in the PVH. In addition to the PVH, Sim1-Cre can also abolish TrkB
expression in some neurons of other brain regions including the cerebral cortex, hippocampus, amygdala, thalamus and DMH (Supplementary Fig. 2a-f).

We crossed Sim1-Cre mice to Ntrk2lox/fox mice, which express a normal amount of TrkB in the absence of Cre41, to produce Ntrk2lox/fox (control) and Sim1-Cre;Ntrk2lox/fox (mutant) mice. In situ hybridization confirmed that Ntrk2 expression was abolished in the PVH of Sim1-Cre;Ntrk2lox/fox mice (Fig. 2b). Male and female Sim1-Cre;Ntrk2lox/fox mice at 16 weeks of age were 45% and 49% heavier than sex-matched control mice, respectively (Fig. 2c, d). The Sim1-Cre;Ntrk2lox/fox mice also had a longer body (Fig. 2e) and larger adipose tissues relative to control mice (Supplementary Fig 2g, h). These results indicate that Sim1-Cre;Ntrk2lox/fox mice develop obesity.

We then determined if increased energy intake and/or reduced energy expenditure contribute to the obesity phenotype displayed by Sim1-Cre;Ntrk2lox/fox mice. At 8 weeks of age, female Sim1-Cre;Ntrk2lox/fox mice daily consumed 24% more food than control mice (Fig. 2f). We employed indirect calorimetry to estimate energy expenditure in mice at 6 weeks of age when control and Sim1-Cre;Ntrk2lox/fox mice had comparable body weights (Fig 2c). Control and Sim1-Cre;Ntrk2lox/fox mice had comparable oxygen consumption (VO2) during the light period when mice are mostly at sleep (Fig. 2g, h), suggesting Sim1-Cre;Ntrk2lox/fox mice have a relatively normal basal metabolic rate. During the dark period, VO2 and locomotor activity in Sim1-Cre;Ntrk2lox/fox mice were reduced by 15% and 51%, respectively, compared with control mice (Fig. 2g-i). These results indicate that TrkB signaling in Sim1-Cre cells promote physical activity and energy expenditure. Collectively, our results indicate that Sim1-Cre;Ntrk2lox/fox mice develop obesity due to increased food intake and reduced energy expenditure.

**Selective Ntrk2 deletion in the adult PVH led to hyperphagic obesity**

Sim1-Cre is expressed in other brain regions in addition to the PVH38 (Supplementary Fig. 2a-f), so the obesity phenotype in Sim1-Cre;Ntrk2lox/fox mice might result from Ntrk2 deletion in non-PVH
neurons or cells. To validate a role for PVH TrkB in the regulation of energy balance, we stereotaxically injected neuron-tropic AAV2, either AAV2-CMV-Cre-GFP or AAV2-CMV-GFP, into the PVH of 8-wk-old female Ntrk2lox/lox mice (Fig. 3a). Injection of AAV2-CMV-Cre-GFP selectively abolished Ntrk2 expression in the PVH (Fig. 3a2). Mice injected with AAV2-CMV-Cre-GFP are divided into two groups based on the extent of AAV infection in the PVH: AAV2-CMV-Cre-GFP (missed) and AAV2-CMV-Cre-GFP (hit) (Supplementary Table 1). Mice in the AAV2-CMV-Cre- 

GFP (hit) group developed severe obesity quickly, compared to mice in the AAV2-CMV-GFP group and the AAV2-CMV-Cre-GFP (Missed) group (Fig. 3b, c). The severity of obesity in AAV-Cre-injected mice had a good correlation with the extent of AAV infection in the PVH (Fig. 3d), but not along needle tracks or in other hypothalamic areas (Supplementary Table 1). These results show that PVH TrkB is critical for the control of energy balance.

Mice in the AAV2-CMV-Cre-GFP (hit) group displayed marked hyperphagia just two weeks after AAV injection and remained hyperphagic 10 weeks after injection (Fig. 3e). These mice had energy expenditure and respiratory exchange ratio comparable to control mice (Fig. 3f, h), whereas their ambulatory activity was trending lower 2 weeks after injection and was reduced 10 weeks after injection (Fig. 3g). These results indicate that PVH TrkB regulates energy balance mainly by suppressing appetite.

We noticed that the extent of AAV infection along a needle track is correlated with injection volume. We sought to further verify the role of PVH TrkB in the control of appetite by injecting female Ntrk2lox/lox mice with a smaller volume of AAV into the PVH to minimize infection in needle tracks and other hypothalamic nuclei. We detected very few AAV-transduced neurons in brain areas other than the PVH (mostly detected in Bregma -0.7 to -0.94 mm) in this batch of mice (Supplementary Fig. 3a1-a3). In the PVH, Ntrk2 gene deletion did not cause neuronal loss during the course of the experiment (Supplementary Fig. 3a4-a6). Mice injected with AAV2-CMV-Cre-GFP displayed the same phenotypes as we observed in the first batch of mice, i.e. severe hyperphagic obesity, increased linear growth and reduced ambulatory activity (Supplementary
Interestingly, even unilateral Ntrk2 gene deletion was sufficient to cause significant obesity (Supplementary Fig. 3b), indicating the extreme importance of PVH TrkB in the control of energy balance. Furthermore, Ntrk2 gene deletion in the PVH also led to obesity in male mice (Supplementary Fig. 3h). We did not detect any toxic effect on PVH neurons from AAV transduction, as bilateral injection of AAV2-CMV-Cre-GFP into the PVH of wild-type mice did not alter body weight (Supplementary Fig. 3i).

Oxytocin neurons in the PVH may play a central role in the control of appetite. Ablation of the oxytocin receptor-expressing neurons in the hindbrain leads to overeating\(^42\). Loss of oxytocin neurons is associated with both Prader-Willi syndrome and SIM1 mutations, each of which leads to insatiable appetite and severe obesity in humans\(^43\)-\(^46\). Because a large number of oxytocin neurons express TrkB in the PVH (Fig. 1b), we investigated whether TrkB signaling suppresses appetite through these neurons by deleting the Ntrk2 gene in oxytocin neurons using the Oxt\(^{Cre}\) mouse strain\(^47\) (Supplementary Fig. 4a). Ntrk2 deletion in oxytocin neurons did not affect body weight in mice of either sex (Supplementary Fig. 4b, c).

Collectively, these selective gene deletion experiments show that signaling through the TrkB receptor potently suppresses appetite through non-oxytocin-expressing PVH neurons. They also indicate that TrkB signaling in the PVH somewhat promotes locomotion without significantly altering energy expenditure.

**PVH\(^{TrkB}\) neurons bidirectionally regulate food intake**

As BDNF potently potentiates neuronal growth and synaptic function\(^19\), Ntrk2 deletion would impair the function of PVH\(^{TrkB}\) neurons. The observation that Ntrk2 deletion in the PVH leads to hyperphagic obesity would implicate PVH\(^{TrkB}\) neurons in the acute regulation of food intake. We tested this hypothesis by manipulating the activity of PVH\(^{TrkB}\) neurons using designer receptors exclusively activated by designer drugs (DREADDs) and their ligand clozapine N-oxide (CNO)\(^48,49\). We expressed stimulatory DREADD hM3D(Gq), inhibitory DREADD hM4D(Gi), or
control mCherry in PVH^{TrkB} neurons by injecting Cre-dependent AAV2-hSyn-DIO-hM3D(Gq)-mCherry, AAV2-hSyn-DIO-hM4D(Gi)-mCherry, or AAV2-hSyn-DIO-mCherry into the PVH of \textit{Ntrk2}^{CreER/+} mice. We subsequently induced the expression of the injected AAV vectors in PVH^{TrkB} neurons by treating the mice with tamoxifen (Fig. 4a, b).

Administration of CNO did not alter food intake of \textit{Ntrk2}^{CreER/+} mice expressing mCherry during either the light or dark cycle or after fasting (Fig. 4c-f), indicating that CNO does not have any detectable nonspecific effect on feeding. Administration of CNO greatly increased food intake of \textit{Ntrk2}^{CreER/+} mice expressing hM4D(Gi)-mCherry during the light cycle when mice do not normally eat much food, compared with vehicle administration (Fig. 4c). This result indicates that PVH^{TrkB} neurons are active to maintain physiological satiation during the light cycle. Interestingly, inhibition of PVH^{TrkB} neurons also increased food intake during the dark cycle when mice are physiologically hungry and ingest the vast majority of their daily energy intake (Fig. 4d), suggesting that the anorexigenic PVH^{TrkB} neurons are not fully silenced when mice are physiologically hungry. Conversely, CNO administration drastically reduced food intake of \textit{Ntrk2}^{CreER/+} mice expressing hM3D(Gq)-mCherry during the dark cycle or after overnight fasting, compared with vehicle administration (Fig. 4e, f). This result indicates that activation of PVH^{TrkB} neurons is sufficient to suppress appetite. Taken together, these chemogenetic experiments indicate that PVH^{TrkB} neurons are partially silenced to allow for feeding when mice are hungry, while being active to maintain physiological satiation during the light cycle, and thus PVH^{TrkB} neurons play a critical role in the regulation of appetite by promoting satiety.

**PVH^{TrkB} neurons project to multiple brain areas**

We sought to identify the downstream sites through which PVH^{TrkB} neurons regulate appetite. To map the projections of PVH^{TrkB} neurons in the brain, we injected Cre-dependent AAV2-CAG-FLEX-tdTomato into the PVH of adult \textit{Ntrk2}^{CreER/+} mice (Fig. 5a1). After tamoxifen treatment, tdTomato nicely labeled PVH^{TrkB} neurons across the rostral-caudal axis (Fig. 5a2-4). PVH^{TrkB}
neurons project to four main brain sites: the VMH (Fig. 5a5), the median eminence (ME; Fig. 5a5), the lateral parabrachial nucleus (LPBN; Fig. 5a6), and the nucleus tractus solitarius (NTS; Fig. 5a8). Lesser projections were detected in the medial parabrachial nucleus (MPBN; Fig. 5a6), the locus coeruleus (LC; Fig. 5a7), the dorsal motor nucleus of the vagus (DMV; Fig. 5a8), and the ventrolateral periaqueductal gray (vlPAG; Supplementary Fig. 5a). In the LPBN, axons of PVHTrkB neurons mainly terminate at the central compartment, which is next to the CGRP (calcitonin gene-related peptide)-marked external compartment50 (Fig. 5b).

The projection to the ME is expected, as TrkB is expressed in a fraction of PVH neurons expressing GHRH (Supplementary Fig. 1d) and oxytocin (Fig. 1b), which project to the ME and the posterior pituitary via the ME, respectively, to release hormones. To validate other putative projection fields, we injected retrograde tracers, Alexa Fluor 488-conjugated cholera toxin subunit B (CTB488) or green retrobead (GRB), into each of these fields in tamoxifen-treated Ntrk2CreERT2;Rosa26Ai9/+ mice. In a true projection field, retrograde tracers would be taken up at axonal terminals and retrogradely transported to the cell bodies of PVHTrkB neurons. Indeed, we found that retrograde tracers injected into the VMH (Fig. 5c), LPBN (Fig. 5d), vlPAG, LC, and NTS (Supplementary Fig. 5) labelled some TrkB-expressing neurons in the PVH. These results show that PVHTrkB neurons project to the central compartment of the LPBN (cLPBN), VMH, NTS, MPBN, DMV, vlPAG, ME and pituitary.

**Projection-specific gene deletion**

In order to determine at which projection PVH TrkB is necessary for the regulation of appetite, we designed a two-virus system for projection-specific gene deletion. In this strategy, one viral vector is a retrograde virus [canine adenovirus 2 (CAV2)51 or retrograde AAV (AAVretro)52] expressing yeast flippase (FLP), whereas the other viral vector is AAV2-Ef1a-fDIO-mCherry-P2A-Cre, in which expression of mCherry-P2A-Cre is dependent on FLP-mediated recombination at two sets of Frt sequences (Fig. 6a). If we stereotaxically inject FLP-expressing retrograde virus into the
LPBN and AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH, the retrograde virus would be taken up at axonal terminals and retrogradely transported to the cell bodies of neurons that project to the LPBN. In the PVH, FLP expressed in neurons that project to the LPBN would mediate recombination between the two sets of Frt sites in AAV2-Ef1a-fDIO-mCherry-P2A-Cre and invert the orientation of the mCherry-P2A-Cre sequence, leading to the expression of mCherry and Cre (Fig. 6a). If the two viral vectors are injected into Ntrk2lox/lox mice, expressed Cre would delete the Ntrk2 gene in PVH neurons that project to the LPBN.

We conducted a proof-of-principle experiment to test this projection-specific gene deletion approach in the well-defined substantia nigra → striatum projection. We injected CAV2-FLPo, which expresses optimized FLP, into the striatum and AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the substantia nigra of Bdnflox/lox mice (Fig. 6b1). Bdnflox/lox mice contains a uniquely floxed Bdnf allele that starts to express β-galactosidase in BDNF-expressing cells when Cre recombines the allele. We detected many mCherry-expressing neurons in the substantia nigra (Fig. 6b2), indicating that CAV2-FLPo was retrogradely transported to the substantia nigra from the striatum and induced mCherry expression from AAV2-Ef1a-fDIO-mCherry-P2A-Cre. Because mCherry and Cre are in the same cistron, mCherry-positive neurons should also express Cre, which would mediate recombination of the Bdnflox allele. Indeed, we found that some mCherry-positive neurons expressed β-galactosidase in the substantia nigra (Fig. 6b2-4), where ~50% dopaminergic neurons express BDNF. As expected, we detected expression of neither mCherry nor β-galactosidase in the substantia nigra when CAV2-FLPo was not injected into the striatum (Supplementary Fig. 6a-d). This experiment shows that our two-virus system works for projection-specific gene deletion.

Deletion of the Ntrk2 gene in PVH neurons projecting to the VMH and LPBN leads to hyperphagia and obesity
We targeted the *Ntrk2* gene in PVH neurons that project to the NTS, VMH and LPBN, the three main projection fields of PVH-TrkB neurons. Retrograde virus CAV2-FLPe-GFP (expressing a fusion protein of GFP and the improved FLP), CAV2-FLPo, or AAV2retro-hSyn-FLPo-T2A-GFP were used to express FLP in cell bodies of afferent neurons. We conducted this study only in female mice. Because *Ntrk2* deletion in the PVH produced more severe obesity in females than males (Fig. 3b and Supplementary Fig. 3h), we used female mice to more sensitively uncover the role of different PVH-TrkB projections in the control of appetite.

To delete the *Ntrk2* gene in PVH neurons projecting to the NTS (PVH-TrkB→NTS neurons), we injected CAV2-FLPe-GFP into the NTS and either AAV2-Ef1a-fDIO-mCherry (control) or AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH in *Ntrk2*<sup>lox/lox</sup> mice (Supplementary Fig. 6e). Because the NTS is a long structure, we infused a mixture of CAV2-FLPe-GFP and GRBs into two sites, the rostral part (Supplementary Fig. 6f1-3) and the caudal part (Supplementary Fig. 6f4-6) of the central NTS. Co-injected GRBs allows us to determine if an injection hits the NTS (Supplementary Fig. 6f). In hit mice, we detected mCherry expression in the PVH (Supplementary Fig. 6g), indicating expression of Cre in AAV2-Ef1a-fDIO-mCherry-P2A-Cre injected mice, which would delete the *Ntrk2* gene in positive neurons. We found comparable body weight (Supplementary Fig. 6h), body composition (Supplementary Fig. 6i) and food intake (Supplementary Fig. 6j) between mutant mice and control mice. These results suggest that TrkB in PVH-TrkB→NTS neurons is not essential for the control of food intake and body weight.

We next targeted the *Ntrk2* gene in PVH neurons projecting to the VMH (PVH-TrkB→VMH neurons) by injecting a mixture of CAV2-FLPo and AAV-GFP into the VMH and either AAV2-Ef1a-fDIO-mCherry or AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH in *Ntrk2*<sup>lox/lox</sup> mice (Fig. 6c1). Co-injected AAV-GFP marks injection sites (Fig. 6c2). In our initial trial, we noticed lesions at CAV2-FLPo injection sites, likely due to an immune response to CAV2. Therefore, we treated *Ntrk2*<sup>lox/lox</sup> mice with the immunosuppressant cyclophosphamide (50 mg/kg, i.p.) once every 2 d
from day -3 to day 13 as previously described\textsuperscript{55}. Ten weeks after CAV2 injection, we did not detect any lesions in the VMH (Fig. 6c2), indicating that cyclophosphamide successfully blocked the immune response to CAV2. In mice with successful viral injection as evidenced by bilateral mCherry expression in the PVH (Fig. 6c3 and 6c4), the Cre group had significantly higher body weight (Fig. 6d), fat mass and lean mass (Fig. 6c), body length (Fig. 6f), and food intake (Fig. 6g). These results show that deleting \textit{Ntrk2} in PVH\textsubscript{TrkB}\textsubscript{→VMH} neurons leads to hyperphagia and obesity, indicating a crucial role for TrkB in PVH\textsubscript{TrkB}\textsubscript{→VMH} neurons in appetite suppression.

Finally, we deleted the \textit{Ntrk2} gene in PVH neurons projecting to the LPBN (PVH\textsubscript{TrkB}\textsubscript{→LPBN} neurons) by injecting AAV2retro-hSyn-FLPo-T2A-GFP into the LPBN and either AAV2-Ef1a-fDIO-mCherry or AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH in \textit{Ntrk2}\textsuperscript{lox/lox} mice (Fig. 7a1). We employed AAV2retro-hSyn-FLPo-T2A-GFP rather than CAV2-FLPo for the PVH \textit{→} LPBN projection, because we found that AAVretro is more efficient in retrograde infection than CAV2 at this projection. AAV2retro-hSyn-FLPo-T2A-GFP expresses GFP at injection sites (Fig. 7a2), allowing us to assess the accuracy of each injection. In mice with successful viral injection as evidenced by GFP expression in the LPBN (Fig. 7a2) and mCherry expression in the PVH (Fig. 7a3 and 7a4), the Cre group had significantly higher body weight (Fig. 7b), fat mass and lean mass (Fig. 7c), body length (Fig. 7d), and food intake (Fig. 7e). These results show that deleting \textit{Ntrk2} in PVH\textsubscript{TrkB}\textsubscript{→LPBN} neurons also leads to hyperphagia and obesity, indicating a crucial role for TrkB in PVH\textsubscript{TrkB}\textsubscript{→LPBN} neurons in the control of food intake.

\textbf{PVH\textsubscript{TrkB} neurons projecting to the LPBN are distinct from those projecting to the VMH and respond to nutritional state}

Because the TrkB receptor at both PVH\textsubscript{TrkB} projections to the VMH and the LPBN is crucial for the control of appetite, we next investigated the possibility that the same subset of PVH\textsubscript{TrkB} neurons send collaterals to the VMH and the LPBN. We stereotaxically injected retrograde tracers CTB488
and Alexa Fluor 594-conjugated CTB (CTB594) into the VMH and LPBN, respectively (Fig. 7f1-3). We found that CTB594 mainly labeled cell bodies in the rostral and medial parts of the PVH, whereas CTB488 largely in the medial and caudal parts of the PVH (Fig. 7f4-7). No neurons were detected to contain both CTB488 and CTB594 (Fig. 7f4-7). These results indicate that two distinct subtypes of PVHTrkB neurons project to the VMH and the LPBN.

The observation that abolishment of Ntrk2 expression in PVHTrkB→VMH and PVHTrkB→LPBN neurons leads to hyperphagic obesity suggests that these two subtypes of neurons respond to changes in nutritional state. We tested this hypothesis in PVHTrkB→LPBN neurons. We injected CTB488 into the LPBN of tamoxifen-treated Ntrk2CreER/+;Rosa26Ai9/+ mice. After the mice were extensively handled, they were fasted overnight and a half of them were refed for 2 h. We found that more CTB488-labeled PVHTrkB neurons expressed Fos in refed mice than in fasted mice (Fig. 7g, h), indicating that refeeding activates PVHTrkB→LPBN neurons. These results together with the findings from Ntrk2 deletion and manipulation of neuronal activity, shows that feeding activates PVHTrkB→VMH and PVHTrkB→LPBN neurons to suppress appetite.

**DISCUSSION**

This study has identified the PVH as a main site where TrkB signaling works to suppress food intake. Using a projection-specific gene deletion strategy we designed, we have further narrowed down the action site of TrkB signaling to two distinct subtypes of PVH neurons that project to the LPBN and the VMH, respectively. Given that BDNF-TrkB signaling is known to potentiate synaptic transmission in the hippocampus, these results suggest that some PVHTrkB neurons are activated to suppress appetite. Indeed, we have found in mice that refeeding activates PVHTrkB→LPBN neurons and that chemogenetic activation of PVHTrkB neurons inhibits food intake during the dark cycle or after overnight food deprivation. Thus, our study indicates that signals
reflecting repletion activate PVH^{TrkB} neurons to promote satiety through their outputs to the LPBN and the VMH.

We found that deletion of the Ntrk2 gene with the Sim1-Cre transgene led to hyperphagia and reduced energy expenditure in mice. This observation is in agreement with the previous finding that BDNF expressed in the PVH suppresses food intake and promotes adaptive thermogenesis\textsuperscript{22}. Collectively, these results demonstrate that BDNF-TrkB signaling plays a critical role in the control of both energy intake and energy expenditure. When we selectively deleted the Ntrk2 gene in the PVH using stereotaxic injection of Cre-expressing AAV, mutant mice displayed marked hyperphagia but normal energy expenditure. It is likely that TrkB signaling in other brain areas that express Sim1-Cre is involved in the regulation of energy expenditure. One of these brain areas could be the DMH, in which Ntrk2 deletion significantly reduces energy expenditure\textsuperscript{28}. Injection of BDNF protein into the PVH was reported to increase energy expenditure\textsuperscript{37}. This could be a result of activation of the TrkB receptor at axonal terminals of neurons that project to the PVH or a non-specific effect of recombinant BDNF.

A genetically defined group of neurons in a specific brain structure usually have multiple projection fields, and the powerful optogenetic approach is commonly employed to uncover the role of the neurons at each projection in animal behaviors. For example, Garfield et al. expressed channelrhodopsin-2 (ChR2) in PVH^{MC4R} neurons and found that light activation of ChR2 at PVH^{MC4R} axonal terminals in the LPBN inhibited food intake, indicating that the PVH^{MC4R} \rightarrow LPBN neurocircuit promotes satiety\textsuperscript{27}. However, this approach is not suitable for uncovering gene function and is not ideal for examination of the long-term effect of altering neuronal activity. The projection-specific gene deletion described here makes it possible to determine the function of a gene in a specific neurocircuit. If deletion of a gene also alters the function of the targeted neurocircuit, the same experiment will also reveal both short-term and long-term impacts of altering the activity of the circuit on behaviors and physiology.

Using the projection-specific gene deletion approach, we have identified two subtypes of
PVH\textsuperscript{TrkB} neurons (PVH\textsuperscript{TrkB→LPBN} neurons and PVH\textsuperscript{TrkB→VMH} neurons) in which TrkB signaling is necessary to suppress appetite. Deletion of the \textit{Ntrk2} gene in one of these two subtypes of neurons led to hyperphagia and obesity. Furthermore, we have found that refeeding activates PVH\textsuperscript{TrkB→LPBN} neurons and that chemogenetic stimulation/inhibition of PVH\textsuperscript{TrkB} neurons greatly decreases/increases food intake, respectively. These results suggest that abolishment of TrkB signaling impairs the function of these two subtypes of neurons, which leads to deficits in transmitting satiation signals to their target neurons in the LPBN and VMH. These results also indicate that the PVH\textsuperscript{TrkB→LPBN} and PVH\textsuperscript{TrkB→VMH} neurocircuits are satiating and that BDNF is a key modulator of the two anorexigenic neurocircuits. As BDNF potently potentiates synaptic transmission\textsuperscript{19}, it is likely that TrkB signaling enhances synaptic transmission in the two subtypes of PVH\textsuperscript{TrkB} neurons. It would be important to understand which neurons activate PVH\textsuperscript{TrkB} neurons in response to refeeding, what are the targets of PVH\textsuperscript{TrkB} neurons in the LPBN and VMH, and how TrkB signaling modulates synaptic function in PVH\textsuperscript{TrkB→LPBN} and PVH\textsuperscript{TrkB→VMH} neurons in future studies.

The vast majority of PVH neurons are glutamatergic neurons\textsuperscript{56}. These neurons have been shown to provide excitatory drive to the AgRP neurons in the arcuate nucleus\textsuperscript{57}, the cLPBN\textsuperscript{27}, and the pre-locus coeruleus (pLC)\textsuperscript{28} to regulate satiety. This study identifies one more neurocircuit out of the PVH, i.e. PVH\textsuperscript{TrkB→VMH}, to regulate satiety.

Although ablation of the oxytocin receptor-expressing neurons in the hindbrain leads to overeating\textsuperscript{42}, ablation of PVH oxytocin neurons in adult mice has no effect on body weight, food intake, or energy expenditure\textsuperscript{47}. Consistent with this observation, we found that deletion of the \textit{Ntrk2} gene in PVH\textsuperscript{OXT} neurons did not affect energy balance. Thus, PVH\textsuperscript{TrkB→LPBN} and PVH\textsuperscript{TrkB→VMH} neurons should be distinct from oxytocin neurons. Previous work shows that LPBN-projecting PVH\textsuperscript{MC4R} (PVH\textsuperscript{MC4R→LPBN}) neurons and PVH\textsuperscript{BDNF} neurons also promote satiety\textsuperscript{22,27}, although it remains unknown where PVH\textsuperscript{BDNF} neurons project to suppress appetite. As we detected low co-
localization of TrkB with either MC4R or BDNF, PVH^{TrkB→LPBN} and PVH^{TrkB→VMH} neurons could be distinct from PVH^{MC4R→LPBN} and PVH^{BDNF} neurons. A recent study shows that PDYN-expressing pLC-projecting PVH (PVH^{PDYN→pLC}) neurons regulate satiety and are distinct from PVH^{MC4R} neurons\(^2\). If PVH^{BDNF} neurons are distinct from PVH^{PDYN→pLC} neurons, at least 5 subtypes of PVH neurons (PVH^{MC4R→LPBN}, PVH^{BDNF}, PVH^{PDYN→pLC}, PVH^{TrkB→LPBN}, and PVH^{TrkB→VMH}) have been identified to promote satiety. It would be important to investigate how these neurons coordinately regulate satiety and body weight. This is especially true for PVH^{MC4R→LPBN} and PVH^{TrkB→LPBN} neurons, which project to the same target field, the cLPBN. It would be intriguing to know whether these two subtypes of neurons innervate the same neurons in the cLPBN and receive inputs from the same afferent neurons. These future studies will provide insights into the organization and function of the neural network that regulates appetite.

ACKNOWLEDGEMENTS

We thank David Ginty for the Ntrk2\(^{CreER}\) mouse strain, Martin Wessendorf for the anti-TRH antibody, and Jessica Houtz and Shaw-wen Wu for critical reading of this manuscript. This work was supported by US National Institutes of Health grants to BX (R01 DK103335 and R01 DK105954).

AUTHOR CONTRIBUTIONS

J.J.A. and B.X. conceived the study. J.J.A., C.E.K. and B.X. designed the study. J.J.A. did colocalization immunohistochemistry and analyzed Sim1-Cre;Ntrk2\(^{lox/lox}\) conditional knockout mice. C.E.K., J.J.A. and G.Y.L. did stereotaxic injection of AAV-Cre-GFP. C.E.K. and J.J.A. analyzed PVH-specific Ntrk2 mutant mice. J.J.A. constructed viral vectors for projection-specific gene deletion, did DREADD experiments, and examined Fos induction after refeeding. J.J.A. constructed pCAV2-FLPe-GFP. E.J.K. produced CAV2-FLPe-GFP and CAV2-FLPo. J.J.A. and
C.E.K. did projection tracing and projection-specific Ntrk2 deletion. J.J.A. and B.X. prepared figures. B.X. and J.J.A. wrote the manuscript with input from all authors.

**METHODS**

**Animals.** Floxed **Ntrk2** (Ntrk2\(^{lox}\), also known as TrkB\(^{lox}\))\(^{41}\), floxed **Ntrk2-LacZ** (Ntrk2\(^{fBZ}\); also known as fBZ)\(^{40}\), and floxed **Bdnf** (Bdnf\(^{lox}\))\(^{53}\) mouse strains were previously described. Ntrk2\(^{lox}\) mice were backcrossed to C57BL/6J mice for at least 15 generations before they were used in this study. Sim1-Cre (stock No: 006395), MC4R-tau-GFP (stock No: 008323), **Rosa26\(^{Ai9}\) [Gt9(ROSA)26Sor tm9CAG-ttdTomato]Hze/J; stock No: 007909] and C57BL6/J (stock No: 000664) mouse strains were obtained from the Jackson Laboratory. The **Ntrk2\(^{CreER/+}\)** (also known as TrkB\(^{CreER}\)) mouse strain\(^{32}\) was kindly provided by Dr. David Ginty at Harvard Medical School. We generated Ntrk2\(^{CreER/+}\);Rosa26\(^{Ai9/+}\) mice by crossing Ntrk2\(^{CreER/+}\) mice to Rosa26\(^{Ai9/+}\) mice. To induce nuclear localization of the CreER fusion protein in mice harboring the Ntrk2\(^{CreER}\) allele, we treated the mice with tamoxifen (2 mg/animal, i.p.) once a day for 7 consecutive days in 6-8-wk-old mice. Animals were used for experiments 7 d after the last tamoxifen injection. Ntrk2\(^{lox/lox}\) mice were crossed with Sim1-Cre;Ntrk2\(^{lox/lox}\) mice to generate Sim1-Cre;Ntrk2\(^{lox/lox}\) mutant mice and Ntrk2\(^{lox/lox}\) control mice. All mice used in this study were maintained in the C56BL6/J genetic background. Mice were maintained on a 12-h/12-h light/dark cycle with *ad libitum* access to water and regular laboratory chow (Teklad Rodent Diet 2019; 3.3 kcal/g energy density, 22% kcal from fat) unless otherwise specified. The Animal Care and Use Committees at The Scripps Research Institute Florida approved all animal procedures used in this study.

**Immunohistochemistry.** For neuropeptide immunohistochemistry, we injected Ntrk2\(^{CreER/+}\);Rosa26\(^{Ai9/+}\) mice with colchicine (20 µg per animal, i.c.v.; Tocris) to impair protein transportation in neuronal processes. Forty-eight hours after colchicine injection, mice were deeply anaesthetized with avertin and transcardially perfused with phosphate buffered saline (PBS),
followed by 4% paraformaldehyde in PBS. Coronal brain sections (40 µm in thickness) were obtained using a sliding microtome (Leica SM2000R). Brain sections were rinsed once with Tris buffered saline (TBS; 10 mM Tris-HCl, 150 mM NaCl, pH7.5), incubated with blocking buffer (0.4% Triton X-100, 1% bovine serum albumin, and 10% goat serum or horse serum in TBS) for 1 h at room temperature, and then incubated with primary antibodies diluted in the blocking buffer overnight at room temperature. The following primary antibodies were used: chicken anti-β-galactosidase (1:3,000; abcam #ab9361), rabbit anti-NeuN (1:1000; Millipore #ABN78), rabbit anti-GFAP (1:400; Sigma #G9269), mouse anti-oxytocin (1:5000; Millipore #MAB5296), rabbit anti-CRH (1:500; Millipore #AB1760), mouse anti-GFP (1:1000; Clontech #632460), rabbit anti-somatostatin (1:500; immunostar #20067), rabbit anti-GHRH (1:500; Immunostar #22938), rabbit anti-vasopressin (1:5000; Millipore #AB1565), mouse anti-tyrosine hydroxylase (1:10,000; Sigma #T1299), rabbit anti-c-Fos antibody (1:5000; abcam #ab208942), rabbit anti-prodynorphin (1:200; abcam #ab11137), and rabbit anti-TRH (1:10,000; generous gift from Dr. Martin Wessendorf, University of Minnesota). After three washes in TBS, sections were incubated with appropriate fluorescent secondary antibodies (1:500; Jackson ImmunoResearch) for 1 h at room temperature. Sections were washed three times in TBS, mounted onto slides, and coverslipped with a mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories). Fluorescent images were captured using a Nikon C2+ confocal microscope or a Leica TCS SP8 microscope.

**Plasmids and viruses.** For generation of pAAV-Ef1a-fDIO-mCherry and pAAV-Ef1a-fDIO-mCherry-P2A-Cre, pAAV-Ef1a-fDIO-EYFP (a gift from Karl Deisseroth; Addgene plasmid #55641) was used as backbone. pAAV-Ef1a-fDIO-EYFP was digested with Ascl and Nhel site to remove EYFP. The sequence encoding mCherry and mCherry-P2A-Cre were obtained by PCR using plasmid pLM-CMV-R-Cre (a gift from Michel Sadelain; Addgene plasmid #27546) as template. PCR products were digested with Ascl and Nhel and cloned into the backbone of pAAV-
Ef1a-fDIO-EYFP to generate plasmid pAAV-Ef1a-fDIO-mCherry and pAAV-Ef1a-fDIO-mCherry-P2A-Cre. pAAV-hSyn-FLPo-T2A-GFP was generated using pAAV-hSynapsin-Flp0 (a gift from Massimo Scanziani; Addgene plasmid #60663) as backbone. We replaced the Flp0 sequence containing a stop codon with a Flp0 without a stop codon using BamHI and HindIII sites to generate an intermediate plasmid. The T2A-GFP sequence was amplified by PCR using plasmid PX461 (a gift from Feng Zhang; Addgene plasmid #48140) as template and inserted into the intermediate plasmid at HindIII site to generate pAAV-hSyn-FLPo-T2A-GFP. AAV2-Ef1a-fDIO-mCherry, AAV2-Ef1a-fDIO-mCherry-P2A-Cre and AAV2retro-hSyn-Flp0-T2A-GFP were packaged by UNC Vector Core. AAV2-CMV-GFP, AAV2-CMV-GFP-Cre and AAV2-CAG-FLEX-tdTomato viruses were purchased from UNC vector Core. AAV2-hSyn-DIO-mCherry, AAV2-hSyn-DIO-hM3Dq-mCherry and AAV2-hSyn-DIO-hM4Di-mCherry were purchased from Addgene.

To construct pCAV2-FLPe-GFP, we inserted the Flp-GFP sequence into the CAV shuttle plasmid\(^5^8\) to generate pShuttle-FLPe-GFP. The FLPe-GFP sequence was isolated from pCAG- FLpe-GFP (a gift from Connie Cepko, Addgene plasmid #13788). The Ascl-PacI fragment of the shuttle construct was purified and used to generate pCAV2-FLPe-GFP through homologous recombination in E. coli as described\(^5^9\). To generate pCAV2-FLPo, we began with pCAV-FLEX\(^{loxP}\)-Flp\(^6^0\). pCAV-FLEX\(^{loxP}\)-Flp contains the CAV-2 genome deleted in the E1 and E3 regions, and a cassette containing a CMV promoter, two loxP sites, an inverted Flp0 open reading frame, and an SV40 polyA signal. pCAV-FLEX\(^{loxP}\)-Flp was incubated with recombinant Cre recombinase (New England Biolabs) and then transformed into DH\(\alpha\) bacteria. A clone containing the FLPo cassette in the 5' → 3' orientation was identified by restriction digestion analyses and denoted pCAV2-FLPo. Viral vectors CAV2-FLPe-GFP and CAV2-FLPo were generated, amplified, and purified as previously described\(^5^8\).
Stereotaxic injection of virus and CTB. The stereotaxic surgeries were performed as previously described. Mice were deeply anesthetized with isoflurane and were placed onto a stereotaxic apparatus (David Kopf, Model 940). A small incision was made to expose the skull, and a small hole was drilled on skull above the injection site. A Nanofil 33-gauge needle (World Precision Instruments, #NF33BV-2) was inserted into the brain and the virus was injected at a rate of 25 nl/min using Microsyringe Pump (World Precision Instruments, Micro4). After infusion, the needle was stayed in the same position for 5 min. Following injections, mice received subcutaneous injection of Loxicom (0.5 mg/kg) to relieve pain. Stereotaxic coordinates from the bregma used for this study were PVH (AP: -0.5 mm, ML: ±0.25 mm, DV: -5.4 mm), VMH (AP: -1.4 mm, ML: ±0.4 mm, DV: -5.95 mm), LPBN (AP: -5 mm, ML: ±1.5 mm, DV: -3.8 mm), vIPAG (AP: -4.72 mm, ML: ±0.68 mm, DV: -2.70 mm), and LC (AP: -5.4 mm, ML: ±0.91 mm, DV: -4.1 mm). Stereotaxic coordinates for the NTS relative to the calamus scriptorius were rostral NTS (AP: +0.85 mm, ML: ±0.58 mm, DV: -0.42 mm) and caudal NTS (AP: -0.0 mm, ML: ±0.26 mm, DV: -0.4 mm). After physiological measurements are completed, animals were perfused with saline and 4% paraformaldehyde and their brains were sliced for examination of injection sites. Mice with missed injections were either assigned to a separate group or excluded in final data analyses.

Physiological measurements. In the Ntrk2 gene deletion experiments, body weight was measured weekly. Body length (naso-anal) was measured from anesthetized mice in the end of each experiment. For food intake, mice were individually housed, and daily food intake was measured over 5 d after 3 d of acclimation. Body composition was determined using a Minispec LF-50/mq 7.5 NMR Analyzer (Brucker Optics). VO₂ and locomotor activity were assessed with a comprehensive lab animal monitoring system (CLAMS, Columbus Instruments). Ambulatory activity was measured as light beam breaks in the XY horizontal plane.
Chemogenetic manipulation of food intake. Mice injected with AAV2-hSyn-DIO-mCherry, AAV2-hSyn-DIO-hM3D(Gq)-mCherry or AAV2-hSyn-DIO-hM4D(Gi)-mCherry were singly housed for at least 2 weeks with daily handling prior to experiment. For food intake measurement during light cycle, mice were transferred to a new cage without food at 7:30 am and injected intraperitoneally with vehicle or CNO (Sigma-Aldrich #C08325) at 8:30 am. Pre-weighed food was then added to each cage at 9:00 am and food intake was measured hourly for 3 h. For food intake measurement during dark cycle, mice were transferred to a new cage without food at 3 pm and injected with vehicle or CNO at 5:30 pm. Pre-weighed food was then added to each cage at 6:00 pm and food intake was measured hourly from 7:00 pm to 9:00 pm. For food intake measurement after overnight fasting, mice were transferred to a new cage with alpha-dri bedding without food at 6:00 pm for overnight fasting. On the following day, mice were injected with vehicle or CNO at 9:30 am and pre-weighed food was added to each cage at 10:00 am and food intake was measured hourly for 3 h. The CNO dosage was 1 mg/kg body weight for mice injected with AAV2-hSyn-DIO-hM3D(Gq)-mCherry and 3 mg/kg body weight for mice injected with AAV2-hSyn-DIO-hM4D(Gi)-mCherry.

In situ hybridization. Freshly dissected mouse brains were quickly frozen in a 2-methylbutane (Fisher Scientific #O3551-4) dry ice bath. Subsequently, 20-µm thick cryostat sections were collected on Superfrost Plus slides (Fisherbrand #12-550-15) and used for in situ hybridization. Radioactive in situ hybridization of brain sections was performed using 35S-labeled riboprobes as previously described. To generate antisense riboprobes, the mouse cDNA sequence for Ntrk2 (GenBank accession number X17647, nucleotides 188-722) was amplified by PCR and cloned into pBluescript II KS (-) plasmid (Stratagene). Antisense probes were synthesized with T3 RNA polymerase (Promega #2083) and labeled with alpha-35S-CTP (PerkinElmer #NEG064H250UC) and alpha-35S-UTP (PerkinElmer #NEG039H250UC). Brain sections were postfixed in 4% paraformaldehyde for 1 h and acetylated for 10 min with 0.1M triethanolamine.
hydrochloride/0.25% acetic anhydride (pH 8.0). After dehydration, hybridization was performed with $^{35}$S labeled probes at 55°C for overnight. After hybridization, sections were treated with RNase A (200 μg/ml, Fisher Scientific # BP2539100) to remove unannealed probes. After dehydration, sections were exposed to Kodak BioMax MR films (Carestream Health) for 3 d. Developed film was scanned at 1,200 dpi for image processing.

**Statistical analysis.** All data are expressed as mean ± SEM. Data were tested using Student’s $t$ test or two-way ANOVA with post hoc Bonferroni’s or Tukey’s multiple comparisons for statistical significance.
References

1. Montague, C.T., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* **387**, 903-908 (1997).

2. Yeo, G.S., et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. *Nat Genet* **20**, 111-112. (1998).

3. Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nat Genet* **20**, 113-114. (1998).

4. Yeo, G.S., et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. *Nat Neurosci* **7**, 1187-1189 (2004).

5. Han, J.C., et al. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. *N Engl J Med* **359**, 918-927 (2008).

6. Zhang, Y., et al. Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**, 425-432 (1994).

7. Tartaglia, L.A., et al. Identification and expression cloning of a leptin receptor, OB-R. *Cell* **83**, 1263-1271. (1995).

8. Huszar, D., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* **88**, 131-141. (1997).

9. Yaswen, L., Diehl, N., Brennan, M.B. & Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. *Nat Med* **5**, 1066-1070. (1999).

10. Rios, M., et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. *Mol Endocrinol* **15**, 1748-1757. (2001).

11. Xu, B., et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. *Nat Neurosci* **6**, 736-742 (2003).

12. Thorleifsson, G., et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet* **41**, 18-24 (2009).
13. Speliotes, E.K., et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nature genetics* **42**, 937-948 (2010).

14. Okada, Y., et al. Common variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations. *Nature genetics* **44**, 302-306 (2012).

15. Wen, W., et al. Meta-analysis identifies common variants associated with body mass index in east Asians. *Nature genetics* **44**, 307-311 (2012).

16. Andermann, M.L. & Lowell, B.B. Toward a Wiring Diagram Understanding of Appetite Control. *Neuron* **95**, 757-778 (2017).

17. Huang, E.J. & Reichardt, L.F. Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci* **24**, 677-736 (2001).

18. Waterhouse, E.G. & Xu, B. New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. *Mol Cell Neurosci* **42**, 81-89 (2009).

19. Park, H. & Poo, M.M. Neurotrophin regulation of neural circuit development and function. *Nature reviews. Neuroscience* **14**, 7-23 (2013).

20. Lee, K.F., et al. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. *Cell* **69**, 737-749 (1992).

21. Baeza-Raja, B., et al. p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. *Cell Rep* **14**, 255-268 (2016).

22. An, J.J., Liao, G.Y., Kinney, C.E., Sahibzada, N. & Xu, B. Discrete BDNF Neurons in the Paraventricular Hypothalamus Control Feeding and Energy Expenditure. *Cell Metab* **22**, 175-188 (2015).

23. Unger, T.J., Calderon, G.A., Bradley, L.C., Sena-Esteves, M. & Rios, M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. *J Neurosci* **27**, 14265-14274 (2007).

24. Yang, H., An, J.J., Sun, C. & Xu, B. Regulation of Energy Balance via BDNF Expressed in Nonparaventricular Hypothalamic Neurons. *Mol Endocrinol* **30**, 494-503 (2016).
25. Liao, G.Y., Li, Y. & Xu, B. Ablation of TrkB expression in RGS9-2 cells leads to hyperphagic obesity. *Molecular metabolism* **2**, 491-497 (2013).

26. Liao, G.Y., Kinney, C.E., An, J.J. & Xu, B. TrkB-expressing neurons in the dorsomedial hypothalamus are necessary and sufficient to suppress homeostatic feeding. *Proc Natl Acad Sci U S A* **116**, 3256-3261 (2019).

27. Garfield, A.S., *et al.* A neural basis for melanocortin-4 receptor-regulated appetite. *Nat Neurosci* **18**, 863-871 (2015).

28. Li, M.M., *et al.* The Paraventricular Hypothalamus Regulates Satiety and Prevents Obesity via Two Genetically Distinct Circuits. *Neuron* (2019).

29. Swanson, L.W. & Sawchenko, P.E. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. *Annu Rev Neurosci* **6**, 269-324 (1983).

30. Biag, J., *et al.* Cyto- and chemoarchitecture of the hypothalamic paraventricular nucleus in the C57BL/6J male mouse: a study of immunostaining and multiple fluorescent tract tracing. *J Comp Neurol* **520**, 6-33 (2012).

31. Simmons, D.M. & Swanson, L.W. Comparison of the spatial distribution of seven types of neuroendocrine neurons in the rat paraventricular nucleus: toward a global 3D model. *J Comp Neurol* **516**, 423-441 (2009).

32. Rutlin, M., *et al.* The cellular and molecular basis of direction selectivity of Adelta-LTMRs. *Cell* **159**, 1640-1651 (2014).

33. Madisen, L., *et al.* A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci* **13**, 133-140 (2010).

34. Fenner, B.M. Truncated TrkB: beyond a dominant negative receptor. *Cytokine & growth factor reviews* **23**, 15-24 (2012).

35. Liu, H., *et al.* Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. *J Neurosci* **23**, 7143-7154 (2003).
36. Wang, C., Bomberg, E., Billington, C., Levine, A. & Kotz, C.M. Brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus reduces energy intake. *Am J Physiol Regul Integr Comp Physiol* **293**, R1003-1012 (2007).

37. Wang, C., Bomberg, E., Billington, C., Levine, A. & Kotz, C.M. Brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus increases energy expenditure by elevating metabolic rate. *Am J Physiol Regul Integr Comp Physiol* **293**, R992-1002 (2007).

38. Balthasar, N., et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell* **123**, 493-505 (2005).

39. Xu, B., et al. Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. *Neuron* **26**, 233-245. (2000).

40. Xu, B., et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. *J Neurosci* **20**, 6888-6897. (2000).

41. Baydyuk, M., et al. TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. *Proc Natl Acad Sci U S A* **108**, 1669-1674 (2011).

42. Baskin, D.G., et al. A new oxytocin-saporin cytotoxin for lesioning oxytocin-receptive neurons in the rat hindbrain. *Endocrinology* **151**, 4207-4213 (2010).

43. Kublaoui, B.M., Gemelli, T., Tolson, K.P., Wang, Y. & Zinn, A.R. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. *Mol Endocrinol* **22**, 1723-1734 (2008).

44. Swaab, D.F., Purba, J.S. & Hofman, M.A. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. *J Clin Endocrinol Metab* **80**, 573-579 (1995).

45. Holder, J.L., Jr., Butte, N.F. & Zinn, A.R. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. *Hum Mol Genet* **9**, 101-108 (2000).

46. Traurig, M., et al. Common variation in SIM1 is reproducibly associated with BMI in Pima Indians. *Diabetes* **58**, 1682-1689 (2009).
47. Wu, Z., et al. An obligate role of oxytocin neurons in diet induced energy expenditure. *PLoS One* **7**, e45167 (2012).

48. Alexander, G.M., et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. *Neuron* **63**, 27-39 (2009).

49. Krashes, M.J., et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *J Clin Invest* **121**, 1424-1428 (2011).

50. Campos, C.A., Bowen, A.J., Roman, C.W. & Palmiter, R.D. Encoding of danger by parabrachial CGRP neurons. *Nature* **555**, 617-622 (2018).

51. Soudais, C., Laplace-Builhe, C., Kissa, K. & Kremer, E.J. Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. *FASEB J* **15**, 2283-2285 (2001).

52. Tervo, D.G., et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. *Neuron* **92**, 372-382 (2016).

53. Liao, G.Y., et al. Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. *Nat Med* **18**, 564-571 (2012).

54. Baydyuk, M., Xie, Y., Tessarollo, L. & Xu, B. Midbrain-derived neurotrophins support survival of immature striatal projection neurons. *J Neurosci* **33**, 3363-3369 (2013).

55. Ariza, L., et al. Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice. *Hum Gene Ther* **25**, 199-211 (2014).

56. Vong, L., et al. Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. *Neuron* **71**, 142-154 (2011).

57. Krashes, M.J., et al. An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. *Nature* **507**, 238-242 (2014).

58. Kremer, E.J., Boutin, S., Chillon, M. & Danos, O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. *J Virol* **74**, 505-512 (2000).
59. Szelechowski, M., Bergeron, C., Gonzalez-Dunia, D. & Klonjowski, B. Production and purification of non replicative canine adenovirus type 2 derived vectors. *Journal of visualized experiments: JoVE*, 50833 (2013).

60. Schwarz, L.A., *et al.* Viral-genetic tracing of the input-output organization of a central noradrenaline circuit. *Nature* **524**, 88-92 (2015).
Figure 1. Co-expression of TrkB with other neuronal markers in the PVH. TrkB-expressing cells are marked by tdTomato in tamoxifen-treated Ntrk2CreER/+/Rosa26Alb/+ mice. (a) Distribution of TrkB-expressing cells in the PVH at 3 rostral-caudal positions. (b-e) Co-expression of TrkB with oxytocin, TRH, PDYN and CRH. (f) Co-expression of tdTomato and EGFP in Ntrk2CreER/+; Rosa26Alb/+; Mc4r-EGFP mice. Arrows denote representative neurons expressing both TrkB and a PVH marker. Scale bars are 50 µm long.
Figure 2. Deletion of the Ntrk2 gene in Sim1-Cre cells led to obesity. (a) β-galactosidase immunohistochemistry of Sim1-Cre;Ntrk2\textsuperscript{lox/lox}\textsuperscript{+} mice, showing Ntrk2 deletion in the PVH. Scale bar, 50 µm. (b) In situ hybridization of brain sections from 4-month-old Ntrk2\textsuperscript{lox/lox} mice (control) and Sim1-Cre;Ntrk2\textsuperscript{lox/lox} mice (mutant) reveals that Ntrk2 gene expression was abolished in the PVH of mutant mice. Arrows denote the PVH. (c) Body weight of female control and mutant mice. n = 5 mice per genotype. Two-way ANOVA with post hoc Bonferroni multiple comparisons; $F_{(1, 104)} = 163.7$, $P < 0.0001$ for genotype; *$P < 0.05$, **$P < 0.01$, and ***$P < 0.001$. (d) Body weight of male
control and mutant mice. \( n = 4 \) controls and 6 mutants. Two-way ANOVA with post hoc Bonferroni multiple comparisons; \( F_{(1, 104)} = 193.5, P < 0.0001 \) for genotype; **\( P < 0.01 \) and ***\( P < 0.001 \). (e) Body length of 8-wk-old female control and mutant mice. \( n = 5 \) controls and 4 mutants. Student’s \( t \) test; **\( P < 0.01 \). (f) Daily food intake of 8-wk-old female control and mutant mice. \( n = 7 \) controls and 6 mutants. Student’s \( t \) test; **\( P < 0.01 \). (g) Distribution of oxygen consumption (\( \text{VO}_2 \)) over a 24-h period in 6-wk-old female mice. The black bar above \( x \) axis indicates the dark cycle. \( n = 7 \) controls and 6 mutants. Two-way ANOVA for genotype; \( F_{(1, 264)} = 14.54, ***P = 0.0002 \). (h) \( \text{VO}_2 \) of 6-wk-old female mice during the light and dark cycles. \( n = 7 \) controls and 6 mutants. Student’s \( t \) test; **\( P < 0.01 \). (D) Locomotor activity of 6-wk-old female mice during the light and dark cycles. \( n = 7 \) controls and 6 mutants. Student’s \( t \) test; **\( P < 0.01 \). Error bars indicate SEM.
Figure 3. Deletion of the Ntrk2 gene in the PVH of adult female mice leads to hyperphagic obesity. (a) Bilateral injection of AAV2-CMV-GFP or AAV2-CMV-Cre-GFP (200 nl) into the PVH of Ntrk2^{lox/lox} mice. GFP fluorescence indicates precise injection of AAV2-CMV-GFP into the PVH bilaterally (a1). In situ hybridization shows abolishment of Ntrk2 expression in the PVH of Ntrk2^{lox/lox} mice injected with AAV2-CMV-Cre-GFP, but not AAV2-CMV-GFP (a2). Arrows denote the PVH. (b) Body weight of Ntrk2^{lox/lox} mice injected with either AAV2-CMV-GFP or AAV2-CMV-Cre-GFP into the PVH bilaterally. Mice injected with AAV2-CMV-Cre-GFP were divided into two groups: AAV2-CMV-Cre-GFP (missed) mice in which there was little viral transduction in the PVH and AAV2-CMV-Cre-GFP (hit) mice in which there was significant viral transduction in the PVH. n = 4 mice for AAV2-CMV-GFP, 5 mice for AAV2-CMV-Cre-GFP (missed), and 6 mice for AAV2-CMV-Cre-GFP (hit). Two-way ANOVA with post hoc Bonferroni multiple comparisons; \( F_{(2, 120)} = 37.13, P < 0.0001 \) for viral injection; \( ** P < 0.01 \) and \( *** P < 0.001 \) for comparisons between AAV2-CMV-Cre-GFP (hit) and AAV2-CMV-Cre-GFP (missed) and AAV2-CMV-GFP or AAV2-CMV-Cre-GFP (missed). (c) Body composition of Ntrk2^{lox/lox} mice 9 weeks after AAV injection. Student’s t test; \( *** P < 0.001 \). (d) Correlation between the extent of AAV2-CMV-Cre-GFP transduction in PVH and body weight at 8 weeks after injection. Data are from both AAV2-CMV-Cre-GFP (hit) and AAV2-CMV-Cre-GFP (missed) groups. (e) Daily food intake of Ntrk2^{lox/lox} mice during week 3 and week 10 post injection. Two-way ANOVA with post hoc Bonferroni multiple comparisons; \( * P < 0.01 \) and \( ** P < 0.001 \). (f) O_2 consumption of Ntrk2^{lox/lox} mice during week 3 and week 10 post injection. Two-way ANOVA with post hoc Bonferroni multiple comparisons; n.s., no significant. (g) Locomotor activity of Ntrk2^{lox/lox} mice during week 3 and week 10 post injection. Two-way ANOVA with post hoc Bonferroni multiple comparisons; n.s. = not significant and \( ** P < 0.001 \). (h) RER of Ntrk2^{lox/lox}
mice during week 3 and week 10 post injection. Two-way ANOVA with post hoc Bonferroni multiple comparisons; n.s. = not significant. Error bars indicate SEM.
Figure 4. Chemogenetic modification of PVH\textsuperscript{TrkB} neuronal activity alters food intake. (a) A diagram showing bilateral injection of AAV2-hSyn-DIO-mCherry, AAV2-hSyn-DIO-hM3D(Gq)-mCherry, or AAV2-hSyn-DIO-hM4D(Gi)-mCherry into the PVH of Ntrk2\textsuperscript{CreER/\textsuperscript{+}} mice. (b) A confocal imaging showing mCherry expression of injected AAV in the PVH. Brain sections were counterstained with DAPI. The scale bar represents 100 $\mu$m. (c) Inhibition of PVH\textsuperscript{TrkB} neurons stimulated food intake during the light cycle. $n = 5$ and 6 mice for AAV2-hSyn-DIO-mCherry (mCherry) and AAV2-hSyn-DIO-hM4D(Gi)-mCherry [hM4D(Gi)] groups, respectively. Two-way ANOVA with post hoc Tukey’s multiple comparisons; $F_{(3, 72)} = 35.23$, $P < 0.0001$ for virus and treatment; ****$p < 0.0001$ when compared to the hM4D(Gi)-vehicle (Veh) group. (d) Inhibition of PVH\textsuperscript{TrkB} neurons stimulated food intake during the dark cycle. $n = 6$ and 6 mice for mCherry and hM4D(Gi) groups,
respectively. Two-way ANOVA with post hoc Tukey’s multiple comparisons; $F_{(3, 76)} = 31.49$, $P < 0.0001$ for virus and treatment; ****$p < 0.0001$ when compared to the hM4D(Gi)-Veh group. (e) Activation of PVH$^{TrkB}$ neurons suppressed food intake during the dark cycle. Two-way ANOVA with post hoc Bonferroni’s multiple comparisons; $F_{(3, 22)} = 17.27$, $P < 0.0001$ for virus and treatment; ****$P < 0.0001$ when compared to the hM3D(Gq)-Veh group. (f) Activation of PVH$^{TrkB}$ neurons suppressed fasting-induced appetite. Two-way ANOVA with post hoc Bonferroni’s multiple comparisons; $F_{(3, 22)} = 10.47$, $P < 0.0001$ for virus and treatment; *$P < 0.05$, **$P < 0.01$ and ****$P < 0.0001$ when compared to the hM3D(Gq)-Veh group. Error bars indicate SEM.
Figure 5. Projections of PVH\textsuperscript{TrkB} neurons. (a) AAV2-CAG-FLEX-tdTomato was unilaterally injected into the PVH of \textit{Ntrk2\textsuperscript{CreER\textsuperscript{+}}} mice (a1). After the mice were treated with tamoxifen, tdTomato-labeled PVH\textsuperscript{TrkB} neurons were present throughout the rostral-caudal axis (a2-a4). Axonal terminals of these neurons were found in the VMH, LPBN, MPBN, LC, NTS and DMV (a5-a8). (b) The LPBN includes the external (e), central (c) and ventral (v) compartments. Axonal terminals of PVH\textsuperscript{TrkB} neurons are mainly in the central compartment, which is next to the CGRP-marked external compartment. (c & d) Retrograde tracers, CTB488 and GRB, were unilaterally injected into the VMH (c) or LPBN (d) of tamoxifen-treated \textit{Ntrk2\textsuperscript{CreER\textsuperscript{+}};Rosa26\textsuperscript{Ai9\textsuperscript{+}}} mice and labeled some tdTomato-expressing PVH\textsuperscript{TrkB} neurons. AP, area postrema; DMV, dorsal motor nucleus of the vagus; ME, median eminence; LC, locus coeruleus; LPBN, lateral parabrachial nucleus; MPBN, medial parabrachial nucleus; NTS, nucleus tractus solitarius; PVH, paraventricular hypothalamus; scp, superior cerebellar peduncle; VMH, ventromedial hypothalamus. Scale bars represent 50 \(\mu\text{m}.\)
Figure 6. Deletion of the Ntrk2 gene in PVH neurons projecting to the VMH leads to hyperphagia and obesity. (a) Diagrams of AAV2-Ef1a-fDIO-mCherry and AAV2-Ef1a-fDIO-mCherry-P2A-Cre viral vectors for FLP-dependent expression of mCherry and Cre. (b) Deletion of the Bdnf gene in substantia nigra neurons projecting to the striatum. CAV2-FLPo (500 nl) and AAV2-Ef1a-fDIO-mCherry-P2A-Cre (200 nl) were stereotaxically injected into the striatum (Stm) and substantia nigra (SN) of Bdnf<sup>lox/lox</sup> mice, respectively (b1). Expression of mCherry and β-galactosidase (β-gal) was detected in the substantia nigra. (c) Deletion of the Ntrk2 gene in PVH neurons projecting to the VMH. A mixture of CAV2-FLPo + AAV2-CMV-GFP (350 nl, 5:1 ratio) and either AAV2-Ef1a-fDIO-mCherry (control) or AAV2-Ef1a-fDIO-mCherry-P2A-Cre (150 nl) were bilaterally injected into the VMH and PVH of Ntrk2<sup>lox/lox</sup> mice, respectively (c1). Co-injected AAV2-CMV-GFP was used to mark CAV2 injection sites (c2). Neurons that are transduced by both CAV2-FLPo and one of the two FLP-dependent AAV vectors would express mCherry (c3 and c4). (d-g) Body weight (d), fat mass and lean mass (e), body length (f), and food intake (g) of female Ntrk2<sup>lox/lox</sup> mice injected with CAV2-FLPo into the VMH and either AAV2-Ef1a-fDIO-mCherry or AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH. Body weight data were analyzed using two-way ANOVA.
with Bonferroni post hoc tests; $F_{(1, 90)} = 124.0, P < 0.0001$ for virus. Other data were analyzed with Student’s t test. n = 6 mice for each group. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ and ****$P < 0.0001$. Scale bars represent 50 μm.
Figure 7. PVH neurons projecting to the LPBN are activated by refeeding and their TrkB expression is crucial for appetite suppression. (a) Deletion of the Ntrk2 gene in PVH neurons projecting to the LPBN. AAV2retro-hSyn-FLPo-T2A-GFP (200 nl) and either AAV2-Ef1a-fDIO-mCherry (control) or AAV2-Ef1a-fDIO-mCherry-P2A-Cre (150 nl) were bilaterally injected into the LPBN and PVH of Ntrk2^{lox/lox} mice, respectively (a1). GFP marks injection sites of AAV2retro-hSyn-FLPo-T2A-GFP (a2). Neurons that are transduced by both AAV2retro-hSyn-FLPo-T2A-GFP and one of the two FLP-dependent AAV vectors would express mCherry (a3 and a4). (b-e) Body weight (b), fat mass and lean mass (c), body length (d), and food intake (e) of female Ntrk2^{lox/lox} mice injected with AAV2retro-hSyn-FLPo-T2A-GFP into the LPBN and either AAV2-Ef1a-fDIO-mCherry or AAV2-Ef1a-fDIO-mCherry-P2A-Cre into the PVH. Body weight data were analyzed using two-way ANOVA with Bonferroni post hoc tests; F(1, 126) = 488.7, P < 0.0001 for virus. Other data were analyzed with Student’s t test. n = 10 mice in the control group and 6 mice in the Cre group. **P < 0.01 and *****P < 0.0001. (f) Retrogradely labeling of PVH neurons. CTB594 and CTB488 were injected into the VMH and the LPBN, respectively (f1-3). Some retrogradely labeled neurons are in the PVH (f4-7). (g & h) Refeeding after overnight food deprivation induced Fos expression in PVH^{TrkB} neurons projecting to the LPBN. Confocal images show colocalization of tdTomato, CTB488 and Fos in the PVH of tamoxifen-treated Ntrk2^{CreER/+};Rosa26^{Ai9/+} mice (g). In these images, tdTomato marks TrkB neurons, CTB488 labels neurons projecting to the LPBN, and Fos indicates activated neurons. Arrowheads denote neurons positive for tdTomato and CTB488, while arrows indicate neurons positive for all three markers. Number of Fos* neurons in PVH^{TrkB→LPBN} neurons under fasting and refeeding conditions was quantified (h). Scale bars represent 50 µm.